The Modern Role of Beta-Blockers in Cardiovascular MedicineThe book provides a concise much-needed update of beta-blockers use cardiovascular area (particularly hypertension and heart failure). It will uncover the clinical inaccuracies of how the UK NICE Committee have "got it wrong" in their recent pronouncements on BBs and hypertension. Beta-blockers (BBs) are a large and important family of therapeutic agents with primary use is in cardiovascular medicine. The therapeutic areas that BB covers include: Ischemic Heart Disease, Hypertension, Heart Failure and Arrhythmias. Explanation of the role of BBs in the treatment of hypertension and why the UK Health Authority (The NICE Committee) have "got it wrong" A current update of the vital role of beta-blockers in the treatment of heart failure, and why some beta-blockers are "ineffective" Provides a total and current update of the role of beta-blockers in cardiovascular medicine. |
Contents
| 1 | |
BetaBlockers and their Effects upon Ischemic Heart Disease Peripheral Vascular Disease Noncardiac Surgery and the Atheromatous Process | 49 |
BetaBlockers and Hypertension | 81 |
BetaBlockers and Cardiac Arrhythmias | 141 |
BetaBlockers and Heart Failure | 173 |
Adverse Reactions | 207 |
| 251 | |
Other editions - View all
The Modern Role of Beta-Blockers in Cardiovascular Medicine J. M. Cruickshank No preview available - 2010 |
Common terms and phrases
ACE inhibitor action activity adverse agents antihypertensive arrhythmias artery associated atenolol benefit beta-blockers bisoprolol blockers blood pressure bucindolol calcium cardiac Cardiol Cardiovasc cardiovascular carvedilol cause central central obesity changes chronic Circulation Clin Pharmacol clinical combination compared comparison contrast coronary Cruickshank JM death decrease diabetes diastolic disease diuretic dose drugs effects elderly end-points et al exercise fall Figure first-line followed function Group heart failure heart rate highly hypertensive patients important improved increase induced inhibition intravenous involving labetalol Lancet left ventricular less levels linked low-dose lower marked metabolic metoprolol moderately mortality muscle myocardial infarction nebivolol nonselective normal occurs oral particularly pindolol placebo plasma prevention propranolol randomised randomized receptor reduced renal resistance response risk selective significant smoking sotalol stroke subjects surgery syndrome systolic hypertension TABLE tachycardia therapy treatment trial UKPDS vascular ventricular